LG Chem Accelerates Development of Immuno-Oncology Drugs for Solid Tumors and Hematologic Cancers

Researchers at LG Chem Life Sciences Division are conducting new drug research. (Photo by LG Chem)

[Asia Economy Reporter Chunhee Lee] LG Chem is accelerating the development of immuno-oncology drugs for the treatment of solid tumors and hematologic cancers.

On the 6th, LG Chem announced that its U.S. immuno-oncology development partner, Cue Biopharma, recently completed preclinical studies on ‘CUE-102’ and selected the final candidate compound to enter the full clinical development phase.

‘CUE-102’ is a drug that activates T cells (immune cells) recognizing and eliminating WT-1 (Wilms Tumor-1) overexpressed in various solid tumors and hematologic cancer cells, thereby inducing a specific immune response. Cancers expressing WT-1 include colorectal cancer, acute myeloid leukemia, ovarian cancer, small cell lung cancer, and triple-negative breast cancer.

Based on preclinical results confirming the proliferation and activation of T cells selectively responding to the WT-1 antigen, Cue Biopharma plans to submit an Investigational New Drug (IND) application for Phase 1 clinical trials to the U.S. Food and Drug Administration (FDA) within the first quarter of this year. LG Chem, which holds development and commercialization rights in the Asian region, plans to initiate Phase 2 clinical trials in Asia based on the Phase 1 clinical data obtained.

Another drug candidate jointly developed using Cue Biopharma’s in vivo immune function modulation platform technology (Immuno-STAT), the head and neck cancer treatment ‘CUE-101,’ is currently in Phase 1 clinical trials in the U.S. LG Chem and Cue Biopharma plan to demonstrate the precision and scalability of the platform technology by accelerating the development of both ‘CUE-101’ and ‘CUE-102.’

This content was produced with the assistance of AI translation services.